Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Somerset’s resubmitted NDA for the selegiline patch Emsam seeks an indication for relapse prevention as well as treatment of depression.